• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


221.1000 DKK 5.4000 2.50%

As of 11:01:48 ET on 07/29/2014.

Snapshot for Genmab A/S (GEN)

Open: 216.6000 Day's Range: 216.6000 - 222.0000 Volume: 149,191
Previous Close: 215.7000 52wk Range: 156.2000 - 260.0000 1-Yr Rtn: +34.00%

Stock Chart for GEN

No chart data available.
  • GEN:DC 221.1000
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 85.2235
Estimated P/E(12/2014) 66.1382
Relative P/E vs. KFX 3.8037
Earnings Per Share (DKK) (ttm) 2.5944
Est. EPS (DKK) (12/2014) 3.3430
Est. PEG Ratio 1.5107
Market Cap (M DKK) 12,533.55
Shares Outstanding (M) 56.69
30 Day Average Volume 148,769
Price/Book (mrq) 6.4867
Price/Sale (ttm) 15.3147
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/13/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil